Hester Biosciences
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Hester Biosciences is currently navigating a pivotal transition from a government-dependent revenue model to a more diversified approach, emphasizing direct-to-farm sales and an expanded product portfolio. Management's focus on operational excellence and the utilization of enhanced manufacturing capabilities, particularly in its BSL-3 and fill-and-finish facilities, positions the company to capitalize on robust underlying demand for preventive animal healthcare. Despite anticipated revenue contraction due to timing issues with government immunization programs and geopolitical challenges, Vista's forecast reflects stable margins supported by improved pricing power in the expanding Pharma APIs and CRAMS industry. The company's strategic initiatives, including market expansion in Africa and the introduction of new products, are expected to bolster its competitive position. However, potential headwinds such as raw material supply constraints and regulatory scrutiny on antibiotic usage in livestock could impact growth. Over the next 12-24 months, Hester's key opportunities lie in leveraging its strong distribution network and expanding its product offerings, while watchpoints include geopolitical risks and execution challenges in new markets
Why We Like This Stock
- Expansion of manufacturing capabilities enhances production capacity and supports market growth
- Strong demand for preventive animal healthcare products underpins revenue potential
- Strategic focus on operational efficiencies and market diversification positions Hester favorably
Things To Watch Out For
- Revenue contraction anticipated due to timing of government immunization programs
- Geopolitical risks in key markets could disrupt growth and operational execution
- Regulatory scrutiny on antibiotic usage may necessitate further investments and impact margins
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 305 | 311 | 333 | 300 | 312 |
| Profit Before Tax (Cr.) | 32 | 40 | 73 | 62 | 65 |
| PBT Margin | 10.5% | 13.0% | 22.0% | 20.5% | 20.9% |
| Net Profit (Cr.) | 21 | 27 | 58 | 49 | 50 |
| Earnings Per Share | 22.4 | 30.7 | 66.0 | 56.1 | 59.3 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming products, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, farm hygiene, vitamins, minerals, and specialty feed supplements for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides Silvectant, a hydrogen peroxide and silver nitrate solution for disinfection of poultry sheds; Hestbac, a probiotic supplement to control pathogenic bacteria; Hestflora, a combined probiotic and prebiotic formulation that supports gut health and performance; AmmoStop, a probiotic blend for odour control and respiratory comfort in poultry farms. It also offers INACTIVATED H9N2 vaccine for low pathogenic avian influenza; ICEFT RTU, a ceftiofur formulation for uterine and bacterial infections; and Inomilk Gel, an oral calcium supplement, as well as operates diagnostic labs for poultry. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.